Stem cell infusions altered immune patterns in frail adults
A two-month follow-up of 12 adults aged 60–80 linked immune changes to physical gains after random assignment to stem cell infusions or placebo.
Non-randomized trial, registered NCT04314011
Limit: Only 12 participants were analyzed in the study
Edited by Boris Djordjevic · AgingResearch.News
Twelve frail adults aged 60–80 were studied in a follow-up analysis of a randomized trial of stem cells from donated human umbilical cords. Seven received the cells and five received placebo. Researchers measured gene activity in individual blood immune cells before treatment and at one week, one month and two months after the first infusion.
The treated group showed an early, temporary rise in the share of one type of T cell, followed by a sustained reduction in B-cell overactivity. B cells make antibodies. Natural killer cells, another immune cell type, showed gene activity suggesting greater cell-killing ability. Reductions in some immune cell groups correlated with gains in grip strength and walking speed. Increases in regulatory T cells, which help restrain immune responses, were linked to better lower-limb function.
Why it matters
Aging-related frailty involves chronic inflammation and immune dysfunction. The authors propose that restoring immune balance may contribute to functional recovery.
Caveats
The analysis measured blood-cell gene activity, and its correlations cannot establish that immune changes caused physical gains. People with active infections, cancer or severe heart disease were excluded; the supplied text does not report adverse events.
From the paper
- Participants
The present follow-up analysis focused on performing PBMCs obtained from 12 participants enrolled in the aforementioned trial.
- Who took part
Then, we performed scRNA-seq on PBMCs from 12 individuals with age-related frailty to investigate the immunomodulatory potential of HUC-MSCs therapy in frail elderly patients.
Results, scRNA-seq Reveals Dynamic Immune Cell Remodeling Post-HUC-MSCs Therapy
- Ages
The original trial was conducted at Shanghai East Hospital (Shanghai, China) and enrolled frail adults aged 60–80 years, with frailty diagnosed according to Fried’s phenotypic criteria.
- Duration
The overall physical performance which encompassed grip strength, four-meter walking test (4MWT), timed up and go (TUG) test, five times sit to stand test (FTSST), were evaluated at 1-month and 2-month post infusion to examine the ability to stand or movement.
- Analyzed for grip strength
Decreases in memory B cell (ρ = −0.72, p = 0.013, n = 11) and naïve B cell proportions (ρ = −0.61, p = 0.047, n = 11) correlated with greater improvement in grip strength, consistent with the attenuation of B cell hyperactivation noted in Section 3.2.
Results, Immune Remodeling Correlates with Clinical Improvement Following HUC-MSCs Therapy
- Limitation
The findings of this study should be interpreted within its exploratory framework and inherent constraints.
- MAIT cells
Strikingly, MAIT cell frequency in peripheral blood surged at 1-week post-HUC-MSC treatment (p = 0.049; ), accompanied by upregulated markers KLRB1, NCR3, and SLC4A10 (p < 0.0001; ).
- B cell hyperactivity
At 2 months, the treated group exhibited a significant reduction in B cell proportions compared to placebo (p = 0.032; ), accompanied by downregulation of B cell-specific markers (CD79A, MS4A1; p < 0.0001; ).
Results, scRNA-seq Reveals Dynamic Immune Cell Remodeling Post-HUC-MSCs Therapy
- Lower-limb function
At 1-month post-treatment, expansion of regulatory T cells (Tregs) positively correlated with improvement in the FTSST (ρ = +0.66, p = 0.019, n = 12), suggesting that greater Treg increases were associated with greater gains in lower-limb function.
Results, Immune Remodeling Correlates with Clinical Improvement Following HUC-MSCs Therapy
Quoted word for word from the full text on PubMed Central.
- Human umbilical cord-derived mesenchymal stem cells
- Immune response
- Grip strength
- Gait speed
- MAIT cells
- Humans
The paper
Tongji University
Frontiers in Immunology, Jul 13, 2026, Open access
doi.org/10.3389/fimmu.2026.1796161PubMed 42564874
Corrected, Jul 23, 2026
